Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They presently have a $75.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 119.81% from the company’s current price.
PFE has been the subject of several other research reports. Barclays decreased their price objective on Pfizer from $40.00 to $38.00 in a report on Tuesday, July 11th. Jefferies Financial Group decreased their price target on Pfizer from $40.00 to $38.00 in a research note on Wednesday, August 2nd. Credit Suisse Group cut Pfizer from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $47.00 to $40.00 in a research note on Thursday, June 29th. HSBC began coverage on shares of Pfizer in a research note on Friday, July 14th. They issued a “buy” rating and a $50.00 target price for the company. Finally, StockNews.com assumed coverage on shares of Pfizer in a research report on Thursday, August 17th. They set a “hold” rating on the stock. Twelve investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $46.35.
Pfizer Trading Up 0.1 %
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.10. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $13.36 billion. Pfizer had a net margin of 27.55% and a return on equity of 28.36%. The firm’s revenue for the quarter was down 54.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.04 earnings per share. As a group, analysts anticipate that Pfizer will post 3.33 earnings per share for the current fiscal year.
Institutional Trading of Pfizer
Several institutional investors have recently added to or reduced their stakes in the company. 25 LLC acquired a new stake in Pfizer in the 1st quarter worth about $25,000. Worth Asset Management LLC acquired a new stake in shares of Pfizer in the first quarter valued at approximately $29,000. Freedom Wealth Alliance LLC bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $35,000. Macroview Investment Management LLC grew its position in Pfizer by 70.0% during the first quarter. Macroview Investment Management LLC now owns 962 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 396 shares in the last quarter. Finally, Steward Financial Group LLC acquired a new position in Pfizer in the 2nd quarter valued at $43,000. 68.05% of the stock is currently owned by institutional investors.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
- Five stocks we like better than Pfizer
- Pros And Cons Of Monthly Dividend Stocks
- Qualcomm and Apple Forge Ahead with New Modem Partnership
- How to Invest in Casino Stocks
- Can These 3 Healthcare Dividend Stocks Deliver Income Growth?
- How to Invest in Insurance Companies: A Guide
- Arm’s Blockbuster IPO: Big Names and High Expectations
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.